Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.32
|
1.53
|
1.40
|
1.34
|
1.54
|
1.42
|
|
|
31 736.83
|
408.00
|
1.32
|
1.45
|
1.56
|
1.29
|
1.56
|
1.30
|
|
|
18 283.91
|
212.00
|
1.43
|
1.50
|
1.46
|
1.42
|
1.52
|
1.46
|
|
|
18 235.49
|
133.00
|
1.45
|
1.48
|
1.64
|
1.48
|
1.64
|
1.51
|
|
|
107 878.19
|
326.00
|
1.66
|
1.69
|
1.90
|
1.63
|
1.90
|
1.63
|
|
|
1 279 333.46
|
3 325.00
|
1.60
|
1.66
|
1.92
|
1.61
|
1.92
|
1.61
|
|
|
120 626.37
|
324.00
|
1.95
|
1.96
|
1.70
|
1.70
|
2.10
|
1.97
|
|
|
357 570.32
|
965.00
|
1.76
|
1.81
|
1.69
|
1.62
|
1.95
|
1.71
|
|
|
248 288.23
|
868.00
|
1.80
|
1.81
|
1.61
|
1.52
|
1.94
|
1.83
|
|
|
3 016 810.83
|
10 811.00
|
1.48
|
1.58
|
1.31
|
1.20
|
1.71
|
1.48
|
|
|
4 616 051.56
|
21 120.00
|
NKGen Biotech is a clinical-stage biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. NKGen’s product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells with increased activity (defined by parameters such as cytotoxicity, cytokine production and activating receptor expression) as compared to the starting NK cell population.